Want to see GB:SVNS full AI Analyst Report?
SVNS Stock Chart & Stats
0.14 p
-0.02 p(-10.97%)
At close: 4:00 PM EDT
0.14 p
-0.02 p(-10.97%)
Day’s Range― - ―
52-Week Range0.12 p - 0.40 p
Previous CloseN/A
Volume29.11M
Average Volume (3M)34.43M
Market Cap
£9.19M
Enterprise Value12.65M
Total Cash (Recent Filing)£1.72M
Total Debt (Recent Filing)£75.00K
Price to Earnings (P/E)―
Beta>-0.01
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding6,806,403,300
10 Day Avg. Volume23,401,787
30 Day Avg. Volume34,434,652
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)2.44
Price to Sales (P/S)0.00
P/FCF Ratio-4.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Financial FlexibilityVery low leverage reduces insolvency risk and gives management optionality to fund operations, restructure, or invest without immediate refinancing. Over a 2–6 month horizon this structural balance-sheet strength lengthens runway and supports negotiating power with lenders or partners despite ongoing losses.
Improving Shareholders' EquityRising equity indicates that the company has built a larger capital cushion to absorb operating losses. This durable improvement supports solvency, reduces short-term default risk, and improves ability to raise incremental capital on less dilutive terms if management pursues financing to stabilize operations.
Prior Revenue Growth Evidence (2022–2023)Historical revenue growth in 2022–2023 shows the company previously achieved demand traction or commercial progress. That structural capability suggests underlying product/market fit potential which, if management restores go-to-market execution, could be a foundation for scalable revenue recovery over the medium term.
Bears Say
Persistent Operating And Net LossesSustained operating and net losses materially weaken long-term viability: they erode returns, limit reinvestment capacity, and reduce management flexibility. Over 2–6 months this structural unprofitability increases the likelihood of further equity dilution or strategic exits unless a credible path to profitability is implemented.
Chronic Negative Cash FlowOngoing operating cash burn and worsening free cash flow are enduring risks that deplete liquidity and force external financing. Structurally this constrains R&D, operations, and strategic options, and raises the prospect of dilutive capital raises or asset sales to sustain the business absent sustained positive cash generation.
Severe Recent Revenue DeteriorationA collapse of reported revenue to near zero is a structural warning: it implies lost customers, halted sales, or suspended commercial activity. This undermines margin recovery and makes medium-term profitability contingent on major operational or commercial turnaround rather than minor tactical fixes.
Solvonis Therapeutics News
SVNS FAQ
What was Solvonis Therapeutics’s price range in the past 12 months?
Solvonis Therapeutics lowest share price was 0.12 p and its highest was 0.40 p in the past 12 months.
What is Solvonis Therapeutics’s market cap?
Solvonis Therapeutics’s market cap is £9.19M.
When is Solvonis Therapeutics’s upcoming earnings report date?
Solvonis Therapeutics’s upcoming earnings report date is Sep 24, 2026 which is in 42 days.
How were Solvonis Therapeutics’s earnings last quarter?
Solvonis Therapeutics released its earnings results on Apr 29, 2026. The company reported -0.001 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.001 p.
Is Solvonis Therapeutics overvalued?
According to Wall Street analysts Solvonis Therapeutics’s price is currently Overvalued.
Does Solvonis Therapeutics pay dividends?
Solvonis Therapeutics does not currently pay dividends.
What is Solvonis Therapeutics’s EPS estimate?
Solvonis Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Solvonis Therapeutics have?
Solvonis Therapeutics has 6,806,403,300 shares outstanding.
What happened to Solvonis Therapeutics’s price movement after its last earnings report?
Solvonis Therapeutics reported an EPS of -0.001 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -10.781%.
Which hedge fund is a major shareholder of Solvonis Therapeutics?
Currently, no hedge funds are holding shares in GB:SVNS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Solvonis Therapeutics
Graft Polymer (UK) Plc, set to become Solvonis Therapeutics plc in January 2025, is dedicated to the research and development of advanced polymer modification technologies and techniques. Its operations span the United Kingdom, Slovenia, and across Europe. The company offers a diverse portfolio of specialized products: GRAFTABOND: A line of graft/block copolymers designed to robustly combine various polymers with materials such as fiberglass, carbon fiber, mineral and natural fillers, and even mixed polymer waste. GRAFTALEN: These are reactive solid super-concentrates engineered to enhance polyolefin rheology, boost e-modulus, act as chain extenders for PET/PBT, and serve as AOX masterbatches. GRAFTAPOR: Comprising porous polymer-carriers, this line is specifically developed for applications involving liquid chemicals. GRAFTAMID: This series includes high-temperature elastomers, based on nanostructured polyolefin-polyamide alloys. They function as advanced hardening modifiers within polyamide compounds or as standalone components in hot melt adhesive formulations. GRAFTAKIT: Offering reactive liquid or solid super-concentrates embedded in polymeric porous media, GRAFTAKIT is used to optimize reaction extrusion and the modification of compounds. GRAFTALLOY: A range of polymer-polymer nano-alloys crafted to significantly improve abrasion and temperature resistance, boost impact strength, and reduce friction. GRAFTASYNT: This line encompasses synthetic products, notably including halogen-free flame retardants. GRAFTAMER: An innovative smart polymer characterized by thermo-reversible crosslinking, self-hardening, self-healing properties, and shape memory capabilities. The company was founded in 2017 and maintains its headquarters in London, United Kingdom.
Technical Analysis
Avingtrans
―
IMI plc
―
Mpac Group PLC
―
Morgan Advanced Materials
―
Smiths Group plc
―